Antiplatelet Resumption Timing in Post-Percutaneous Coronary Intervention Gastrointestinal Bleeding

Area of Science:

• Cardiology
• Gastroenterology
• Clinical Pharmacology

Background:

• Managing antiplatelet therapy in patients with gastrointestinal bleeding (GIB) after percutaneous coronary intervention (PCI) involves balancing rebleeding risk against clinical vascular events.
• Dual antiplatelet therapy (DAPT) is standard post-PCI, but increases bleeding risk during GIB events.

Purpose of the Study:

• To evaluate the impact of the timing of antiplatelet resumption after endoscopic treatment on GIB recurrence and clinical vascular events.
• To determine the optimal window for resuming antiplatelet therapy to minimize adverse outcomes.

Main Methods:

• A retrospective nationwide cohort study was conducted using the Vizient Clinical Database.
• Patients hospitalized with GIB after PCI and on DAPT were analyzed.
• Co-primary outcomes included 30-day rebleeding and 90-day clinical vascular events, assessed via multivariable Cox regression.

Main Results:

• Resuming antiplatelet therapy more than 7 days post-endoscopy was linked to lower rebleeding rates (HR 0.66) but higher vascular event rates (HR 1.18) compared to resumption within 1 day.
• Similar trade-offs were observed for resuming therapy more than 3 days post-endoscopy.
• These trends were consistent across upper and lower GIB presentations.

Conclusions:

• Delaying antiplatelet resumption beyond 7 days post-endoscopy for GIB after PCI decreases rebleeding but increases vascular events.
• Resumption within 3-4 days appears to offer the best balance between reducing rebleeding and preventing clinical vascular events.
• Personalized antiplatelet management is crucial to optimize outcomes in this high-risk patient population.